Stock Traders Purchase High Volume of Call Options on Boston Scientific (NYSE:BSX)

Boston Scientific Corporation (NYSE:BSX) saw unusually large options trading on Wednesday. Stock traders bought 22,241 call options on the company. This is an increase of approximately 54% compared to the typical daily volume of 14,417 call options.

Analysts Set New Price Targets

A number of analysts have recently weighed in on BSX shares. Wells Fargo & Company increased their price target on Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. The Goldman Sachs Group reiterated a “buy” rating and set a $124.00 price target on shares of Boston Scientific in a research report on Wednesday. Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 11th. Truist Financial increased their price target on Boston Scientific from $125.00 to $129.00 and gave the stock a “buy” rating in a research report on Wednesday, October 1st. Finally, UBS Group raised their target price on Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Thursday, July 24th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $121.71.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the transaction, the director owned 18,479 shares of the company’s stock, valued at $1,959,328.37. This trade represents a 17.79% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,469,268. This represents a 42.32% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 174,214 shares of company stock worth $17,972,457. 0.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Boston Scientific

Large investors have recently modified their holdings of the business. Steph & Co. acquired a new position in shares of Boston Scientific during the 3rd quarter worth about $25,000. Financial Consulate Inc. acquired a new position in shares of Boston Scientific during the 3rd quarter worth about $25,000. 1248 Management LLC acquired a new stake in Boston Scientific in the 1st quarter valued at about $26,000. FWL Investment Management LLC acquired a new stake in Boston Scientific in the 2nd quarter valued at about $26,000. Finally, Y.D. More Investments Ltd acquired a new stake in Boston Scientific in the 1st quarter valued at about $27,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $103.66 on Thursday. The firm has a market cap of $153.60 billion, a PE ratio of 61.70, a PEG ratio of 2.40 and a beta of 0.61. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific has a 1-year low of $80.64 and a 1-year high of $109.50. The company has a fifty day moving average price of $101.22 and a 200 day moving average price of $101.85.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same period in the prior year, the business earned $0.63 EPS. The company’s revenue for the quarter was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Research analysts predict that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.